Tato stránka byla automaticky přeložena a přesnost překladu není zaručena. Podívejte se prosím na anglická verze pro zdrojový text.

OPN-375 Účinnost a bezpečnost u dospívajících s bilaterálními nosními polypy

15. září 2026 aktualizováno: Optinose US Inc.

16týdenní randomizovaná dvojitě zaslepená placebem kontrolovaná paralelní skupinová multicentrická studie hodnotící účinnost a bezpečnost OPN-375 186 μg dvakrát denně u dospívajících s bilaterálními nosními polypy následovaná 12týdenní otevřenou léčebnou fází

This is a 16-Week Randomized, Double-Blind, Placebo Controlled, Parallel-Group, Multicenter Study Evaluating the Efficacy and Safety of OPN-375 186 μg Twice a Day (BID) in Adolescents with Bilateral Nasal Polyps followed by a 12-Week Open-Label Treatment Phase. The total planned number of subjects is approximately 72 adolescents (12-17 years of age) who will be randomly assigned to receive 1 of 2 study treatments using a 2:1 ratio (OPN-375 186 μg: Placebo). For the PK sub-study, up to 14 subjects will be enrolled to obtain 10 completers.

Přehled studie

Postavení

Dokončeno

Intervence / Léčba

Detailní popis

The primary objective of this study is to evaluate the efficacy of intranasal administration of OPN-375 186 μg Twice a Day (BID) versus placebo in adolescents with bilateral nasal polyposis and nasal congestion by analyzing the reduction of nasal congestion/obstruction symptoms at the end of Week 4 measured by the 7-day average instantaneous morning diary symptom scores and the reduction in total polyp grade at Week 16 as determined by a nasal polyp grading scale score measured using a 0 to 6 point severity grading scale.

Typ studie

Intervenční

Zápis (Aktuální)

40

Fáze

  • Fáze 3

Kontakty a umístění

Tato část poskytuje kontaktní údaje pro ty, kteří studii provádějí, a informace o tom, kde se tato studie provádí.

Studijní místa

      • Buenos Aires, Argentina, C1411ABE
        • Fundacion CIDEA
      • Buenos Aires, Argentina, C1425BEN
        • InAER - Investigaciones en Alergia y Enfermedades Respiratorias
      • Buenos Aires, Argentina, C1180AAX
        • Sanatorio Guemes
      • Corrientes, Argentina, W3400AVV
        • Instituto de Asma Alergia y Enfermedades Respiratoria (IAAER)
      • Mendoza, Argentina, M5500CCG
        • Centro Medico INSARES
    • Córdoba Province
      • Río Cuarto, Córdoba Province, Argentina, X5008AEV
        • Instituto Medico Rio Cuarto
    • Santa Fe Province
      • Rosario, Santa Fe Province, Argentina, S2000DEJ
        • Instituto Medico de la Fundacion de Estudios Clinicos - Consultorios Integrados Rosario
      • Rosario, Santa Fe Province, Argentina, S200DBS
        • Centro de Investigaciones Clinicas - Instituto de la Salud Rosario
    • Tucumán Province
      • San Miguel de Tucumán, Tucumán Province, Argentina, T4000IHE
        • Clinica Mayo, UMCB
    • Arizona
      • Gilbert, Arizona, Spojené státy, 85234
        • San Tan Allergy & Asthma
    • California
      • Bakersfield, California, Spojené státy, 93301
        • Kern Research
      • Fresno, California, Spojené státy, 93720
        • Central California Clinical Research
      • Los Angeles, California, Spojené státy, 90027
        • Children's Hospital of Los Angeles
      • Los Angeles, California, Spojené státy, 90006
        • Sensa Health
      • Orange, California, Spojené státy, 92868
        • Children's Hospital of Orange County
      • Redwood City, California, Spojené státy, 94063
        • Allergy and Asthma Consultants
      • Roseville, California, Spojené státy, 95661
        • Sacramento ENT
      • San Diego, California, Spojené státy, 92123
        • Rady Children's Hospital San Diego
    • Colorado
      • Aurora, Colorado, Spojené státy, 80045
        • Children's Hospital Colorado
    • Georgia
      • Atlanta, Georgia, Spojené státy, 30322
        • Children's Healthcare of Atlanta
    • Illinois
      • Chicago, Illinois, Spojené státy, 60657
        • Chicago ENT
    • Kentucky
      • Louisville, Kentucky, Spojené státy, 40205
        • Kentuckiana ENT
    • New York
      • Rochester, New York, Spojené státy, 14642
        • University of Rochester
    • North Carolina
      • Charlotte, North Carolina, Spojené státy, 28204
        • Allergy Asthma & Immunology Research Institute
    • Oklahoma
      • Oklahoma City, Oklahoma, Spojené státy, 73120
        • Allergy, Asthma & Clinical Research Center
      • Tulsa, Oklahoma, Spojené státy, 74136
        • Vital Prospects Clinical Research Institute, P.C.
    • South Carolina
      • Orangeburg, South Carolina, Spojené státy, 29118
        • Carolina ENT
    • Texas
      • San Antonio, Texas, Spojené státy, 78229
        • STAAMP Research
    • Utah
      • Salt Lake City, Utah, Spojené státy, 84132
        • University of Utah
    • Virginia
      • Norfolk, Virginia, Spojené státy, 23507
        • Eastern Virginia Medical School - Otolaryngology
    • Washington
      • Spokane Valley, Washington, Spojené státy, 99216
        • Spokane ENT

Kritéria účasti

Výzkumníci hledají lidi, kteří odpovídají určitému popisu, kterému se říká kritéria způsobilosti. Některé příklady těchto kritérií jsou celkový zdravotní stav osoby nebo předchozí léčba.

Kritéria způsobilosti

Věk způsobilý ke studiu

12 let až 17 let (Dítě)

Přijímá zdravé dobrovolníky

Ne

Pohlaví způsobilá ke studiu

Všechno

Popis

Inclusion Criteria:

  1. Male or female subjects aged 12 to 17 years, inclusive, at time of Visit 1 (Screening).

  2. Female subjects, if sexually active, must,

    1. be practicing an effective method of birth control (e.g., prescription oral contraceptives, contraceptive injections, contraceptive patch, intrauterine device, double-barrier method [e.g., condoms, diaphragm, or cervical cap with spermicidal foam, cream, or gel], or male partner sterilization) before entry and throughout the study, or
    2. be surgically sterile (have had a hysterectomy or bilateral oophorectomy, tubal ligation, or otherwise be incapable of pregnancy), or
    3. be abstinent.
  3. All female subjects not documented to be infertile (e.g., infertility due to congenital abnormality or surgical sterilization) must have a negative serum or urine beta-human chorionic gonadotropin (hCG) at Visit 1 (Screening) and a negative urine pregnancy test at the Visit 2 (Day 1/Randomization/Baseline).

  4. Must have bilateral nasal polyposis with a grade of 1 to 3 in each of the nasal cavities as determined by a nasal polyp grading scale score measured by nasoendoscopy at Visit 1 (Screening).

  5. Must report at least mild symptoms of nasal congestion/obstruction as demonstrated by an average morning nasal congestion/obstruction score of at least 1.0 over a 7 day period during the single-blind run-in period. (Subjects not meeting this inclusion criterion may be re-screened once after at least 4 weeks.)

  6. Subjects with comorbid asthma must be stable, defined as no exacerbations (e.g., no emergency room visits, hospitalization, or oral or parenteral steroid use) within the 3 months before Visit 1 (Screening). Subjects who received inhaled corticosteroids are required to be on no more than a moderate dosage regimen as defined by 2015 Global Initiative for Asthma Guidelines (GINA) for 1 month before Visit 1 (Screening) and to be expected to remain on it throughout the study (GINA 2015). Subjects receiving inhaled fluticasone alone or in combination may not participate in the PK sub-study.

  7. Must be able to cease treatment with intranasal medications including, but not limited to, intranasal oxymetazoline or any other decongestants, intranasal antihistamines, intranasal steroids, intranasal sodium cromolyn, nasal atropine, nasal ipratropium bromide, inhaled corticosteroids (except permitted doses listed above for asthma) at Visit 1 (Screening). [Note: intranasal antibiotics and saline are permissible]

  8. If taking oral antihistamines, must be on a stable regimen for at least 2 weeks prior to Visit 1 (Screening), and agree to not change the dose of these medications until after Visit 3 (Week 4) of the study.

  9. Subjects (with assistance from parent or legal guardian if needed) must demonstrate the ability to complete the daily diary during the run-in period to be eligible for randomization.

  10. Must demonstrate correct use of the demo EDS.

  11. Must be capable, in the opinion of the investigator, of providing assent and the appropriate parent(s) or guardian must provide an informed consent to participate in the study.

Exclusion Criteria:

  1. Pregnancy or lactation
  2. Has a history of cystic fibrosis
  3. Have used XHANCE (fluticasone propionate) nasal spray within the past 2 months
  4. Inability to achieve bilateral nasal airflow for any reason, including nasal septum deviation
  5. Inability to examine both nasal cavities for any reason, including severe nasal septum deviation
  6. Have known history of nasal septum erosion, ulceration or perforation, or evidence of such lesion on Visit 1 (Screening) nasal examination/nasoendoscopy
  7. Other significant nasal pathology or abnormal anatomy
  8. Has had any episode of epistaxis with frank bleeding in the 3 months before Visit 1 (Screening)
  9. History of more than 5 sinus or nasal surgeries for either nasal polyps or nasal/sinus inflammation (lifetime)
  10. Have had any surgery on the nasal septum
  11. History of sinus or nasal surgery within 6 months before Visit 1 (Screening)
  12. History of any surgical procedure that prevents the ability to accurately diagnose or grade polyps
  13. Current, ongoing rhinitis medicamentosa (rebound rhinitis)
  14. Have significant oral structural abnormalities (e.g., a cleft palate)
  15. History of Churg-Strauss syndrome or dyskinetic ciliary syndromes
  16. Purulent nasal infection (recent fever or symptoms of lethargy), acute sinusitis, or upper respiratory tract infection within 2 weeks before Visit 1 (Screening). Potential subjects presenting with one of these infections may be rescreened after 4 weeks.
  17. Have an allergy, hypersensitivity, or contraindication to corticosteroids or steroids
  18. Have a hypersensitivity to any excipients in the study drug
  19. Exposure to any glucocorticoid treatment with potential for systemic effects (e.g., oral or parenteral steroids, high dose topical steroids) within 1 month before Visit 1 (Screening); except as noted in inclusion criteria for subjects with comorbid asthma
  20. Have received mepolizumab (Nucala®), reslizumab (Cinquair®), dupilumab (Dupixent®), omalizumab (Xolair®), or benralizumab (Fasenra™) within 6 months of Visit 1
  21. Have nasal or oral candidiasis
  22. Have taken a potent CYP3A4-inhibitor within 14 days before Visit 1 (Screening)
  23. Any serious or unstable concurrent disease, psychiatric disorder, or any significant concomitant medical condition that, in the opinion of the investigator could confound the results of the study or could interfere with the subject's participation or compliance in the study, or pose a specific risk to the subject due to study participation
  24. History or current diagnosis of any form of glaucoma or ocular hypertension (i.e., >21 mm Hg)
  25. History of intraocular pressure elevation on any form of steroid therapy
  26. Current diagnosis of the presence (in either eye) of a cataract of Grade 1 or greater as defined on the Eye Examination Worksheet OR, less than a Grade 1 cataract with associated visual impairment
  27. A recent (within 1 year of Visit 1 [Screening]) history of drug or alcohol abuse or dependence
  28. Positive urine drug screen at screening visit for stimulants, opioids, or cocaine
  29. Have participated in an investigational drug clinical trial within 30 days of Visit 1 (Screening)
  30. Parents, guardian or caregivers of the subject who are employees of the investigator or study center, with direct involvement in the proposed study or other studies under the direction of that investigator or study center, as well as family members of the employees or the investigator.

Studijní plán

Tato část poskytuje podrobnosti o studijním plánu, včetně toho, jak je studie navržena a co studie měří.

Jak je studie koncipována?

Detaily designu

  • Primární účel: Léčba
  • Přidělení: Randomizované
  • Intervenční model: Paralelní přiřazení
  • Maskování: Dvojnásobek

Zbraně a zásahy

Skupina účastníků / Arm
Intervence / Léčba
Aktivní komparátor: OPN-375 186 μg BID

Double-Blind Treatment Phase: OPN-375 186 μg BID x 16 weeks

Open-Label Extension Phase: OPN-375 186 μg BID x 12 weeks

OPN-375, BID

Komparátor placeba: Placebo

Double-Blind Treatment Phase: Matching Placebo BID x 16 weeks

OPN-375, BID

Co je měření studie?

Primární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Change in nasal congestion/obstruction symptoms (mild, moderate, severe) at the end of Week 4
Časové okno: 4 Weeks

Change in nasal congestion/obstruction symptoms at the end of Week 4 measured by the 7-day average instantaneous morning (AM) diary symptom scores (ADS7-IA). The nasal symptom scale is what is used to score the nasal congestion/obstruction score, which is recorded in the diary. Nasal symptom scale is graded on a scale of 0=no symptom, 1=mild symptom, 2=moderate symptom, 3=severe symptom.

4 Weeks
Mean change from baseline at Week 16 in total polyp grade
Časové okno: 16 Weeks

Change in total polyp grade (sum of scores from both nasal cavities) at Week 16 as determined by a nasal polyp grading scale score measured using a 0 to 6 point severity grading scale, with 0 (no polyps) to 3 (severe polyps) points per nostril

16 Weeks

Sekundární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Change in bilateral polyp grade over time
Časové okno: 16 Weeks

nasal polyp grading scale score measured using a 0 to 6 point severity grading scale, with 0 (no polyps) to 3 (severe polyps) points per nostril

16 Weeks
Percentage of subjects with a ≥1 point improvement in polyp grade
Časové okno: 16 Weeks

nasal polyp grading scale score measured using a 0 to 6 point severity grading scale, with 0 (no polyps) to 3 (severe polyps) points per nostril

16 Weeks
Percentage of subject with a grade of 0 on at least one side of the nose
Časové okno: 16 Weeks

nasal polyp grading scale score measured using a 0 to 6 point severity grading scale, with 0 (no polyps) to 3 (severe polyps) points per nostril

16 Weeks
Change in diary symptom scores for the symptoms of nasal congestion/obstruction, measured as instantaneous and reflective scores for the morning and the afternoon (AM and PM scores)
Časové okno: 16 Weeks

The Nasal Symptom Scale is graded on a scale of 0 (no symptom) to 3 (Severe symptom)

16 Weeks
Change in diary symptom scores for the symptoms of rhinorrhea, measured as instantaneous and reflective scores for the morning and the afternoon (AM and PM scores)
Časové okno: 16 Weeks

The Nasal Symptom Scale is graded on a scale of 0 (no symptom) to 3 (Severe symptom)

16 Weeks
Change in diary symptom scores for the symptoms of facial pain or pressure, measured as instantaneous and reflective scores for the morning and the afternoon (AM and PM scores)
Časové okno: 16 Weeks

The Nasal Symptom Scale is graded on a scale of 0 (no symptom) to 3 (Severe symptom)

16 Weeks
Change in diary symptom scores for the sense of smell, measured as instantaneous and reflective scores for the morning and the afternoon (AM and PM scores)
Časové okno: 16 Weeks

Sense of smell will be scored on a scale from 0 (normal) to 3 (absent, no sense of smell)

16 Weeks
The proportions of subjects who have reductions in the AM and PM, instantaneous and reflective, average nasal congestion/obstruction symptom scores by 0.5 or more points from baseline to the end of the double-blind treatment phase
Časové okno: 16 Weeks

The Nasal Symptom Scale is graded on a scale of 0 (no symptom) to 3 (Severe symptom)

16 Weeks
Subjects will assess their global impression of change since starting the study drug using the PGIC scale
Časové okno: 16 Weeks

Subject global impression of change will be assessed using a subject-completed PGIC scale, with a single question rated from 1=very much improved to 7=very much worse

16 Weeks
Subjects will assess their change in quality of life since starting the study drug using the quality of life questionnaire (SN-5).
Časové okno: 16 Weeks

Quality of life assessment using the SN-5 Questionnaire, a subject/parent-completed questionnaire that consists of 5 specific symptoms-related questions (answered on a 7-point Likert scale on the frequency of symptoms, 1=none of the time, 7=all of the time), and 1 general overall quality of life question (answered on a visual analog scale from 0 to 10, worst to best).

16 Weeks
Proportion of subjects eligible for surgical intervention (independent of actual surgery performed)
Časové okno: Visit 1 (Screening) and Visit 6 (Week 16/ End of Double-Blind/Early Termination)

The assessment criteria are as follows:

  • Subject has had moderate symptoms of congestion from nasal polyposis for at least 3 months.
  • Subject continues to suffer from at least moderate symptoms despite use of topical steroids at conventional doses for at least 6 weeks.
  • Subject continues to suffer from at least moderate symptoms despite use (or previous use) of saline lavage for at least 6 weeks.
  • Subject has endoscopically visualized bilateral nasal polyposis of at least moderate severity (nasal polyp grading score > 2 in at least 1 nostril). Also assess each subject's eligibility for surgery based on specific of criteria (see Section 12) independent of whether the subject actually undergoes surgery.
Visit 1 (Screening) and Visit 6 (Week 16/ End of Double-Blind/Early Termination)

Další výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Posouzení bezpečnosti ze sběru informací pro souběžné užívání léků
Časové okno: 16 týdnů
16 týdnů
Assessment of safety from physical examination-measuring weight
Časové okno: Visit 1 (Screening) and Visit 6 (Week 16/ End of Double-Blind/Early Termination)

Assessment of safety from physical examination-weight measured in kg or lb

Visit 1 (Screening) and Visit 6 (Week 16/ End of Double-Blind/Early Termination)
Assessment of safety from physical examination-measuring height
Časové okno: Visit 1 (Screening) and Visit 6 (Week 16/ End of Double-Blind/Early Termination)

Assessment of safety from physical examination-height measured in cm or in

Visit 1 (Screening) and Visit 6 (Week 16/ End of Double-Blind/Early Termination)
Assessment of safety by recording the severity of AEs
Časové okno: 16 Weeks

Assessment of safety by measuring severity of AEs using scale with 1=mild, 2=moderate, 3=severe

16 Weeks
Assessment of safety by nasal examination
Časové okno: 16 Weeks

Assessed in nasal examination worksheet which includes recording the presence of any epistaxis, septal erosion/perforation, ulceration/erosion of area other than septum. If present, the nostril location is also recorded, along with severity, and if there is any relation to an injury or trauma

16 Weeks
Assessment of safety by ocular examination-visual acuity
Časové okno: Visit 1 (Screening) and Visit 6 (Week 16/ End of Double-Blind/Early Termination)

Assessment of safety by performing visual acuity test assessment using eye chart. Separate recording for each eye in the form of a fraction, 20/...

Visit 1 (Screening) and Visit 6 (Week 16/ End of Double-Blind/Early Termination)
Assessment of safety by ocular examination-Intraocular Pressure
Časové okno: Visit 1 (Screening) and Visit 6 (Week 16/ End of Double-Blind/Early Termination)

Assessment of safety by averaging intraocular pressure measurement of 2 or 3 measurements to determine if it is >21mmHg

Visit 1 (Screening) and Visit 6 (Week 16/ End of Double-Blind/Early Termination)
Assessment of safety by ocular examination-Cataract Evaluation
Časové okno: Visit 1 (Screening) and Visit 6 (Week 16/ End of Double-Blind/Early Termination)

Cataracts should be again assessed present or absent, If cataract is diagnosed, cataract type per localization should be specified and cataract should be graded 1=mild, 2=moderate, 3=pronounced, 4=severe

Visit 1 (Screening) and Visit 6 (Week 16/ End of Double-Blind/Early Termination)
Assessment of safety measuring vital signs (blood pressure)
Časové okno: 16 Weeks

Includes systolic and diastolic blood pressure measurements in millimeter of mercury (mmHg)

16 Weeks
Assessment of safety measuring vital signs (pulse)
Časové okno: 16 Weeks

measure pulse in beats per minute (bpm)

16 Weeks
Assessment of pharmacokinetics - AUC(0-t) (pg*hr/mL)
Časové okno: 8 hours, 1 to 2 weeks before randomization

PK Laboratory to determine the concentrations of fluticasone propionate [AUC(0-t) (pg*hr/mL) measurement] in human plasma using high performance liquid chromatography (HPLC) with mass spectrometric detection. Approximately 5 mL of blood is collected from each subject at 10 different timepoints over an 8-hour period, for a total of 50 mL. The timepoints are: Pre-dose; 5 minutes, 10 minutes, 15 minutes, 30 minutes, 1 hour, 1.5 hours, 3 hours, 6 hours and 8 hours post-dose.

8 hours, 1 to 2 weeks before randomization
Assessment of pharmacokinetics - AUC(0-∞) (pg*hr/mL)
Časové okno: 8 hours, 1 to 2 weeks before randomization

PK Laboratory to determine the concentrations of fluticasone propionate [AUC(0-∞) (pg*hr/mL) measurement] in human plasma using high performance liquid chromatography (HPLC) with mass spectrometric detection. Approximately 5 mL of blood is collected from each subject at 10 different timepoints over an 8-hour period, for a total of 50 mL. The timepoints are: Pre-dose; 5 minutes, 10 minutes, 15 minutes, 30 minutes, 1 hour, 1.5 hours, 3 hours, 6 hours and 8 hours post-dose.

8 hours, 1 to 2 weeks before randomization
Assessment of pharmacokinetics - AUCex (%)
Časové okno: 8 hours, 1 to 2 weeks before randomization

PK Laboratory to determine the concentrations of fluticasone propionate [AUCex (%) measurement] in human plasma using high performance liquid chromatography (HPLC) with mass spectrometric detection. Approximately 5 mL of blood is collected from each subject at 10 different timepoints over an 8-hour period, for a total of 50 mL. The timepoints are: Pre-dose; 5 minutes, 10 minutes, 15 minutes, 30 minutes, 1 hour, 1.5 hours, 3 hours, 6 hours and 8 hours post-dose.

8 hours, 1 to 2 weeks before randomization
Assessment of pharmacokinetics - Cmax (pg/mL)
Časové okno: 8 hours, 1 to 2 weeks before randomization

PK Laboratory to determine the concentrations of fluticasone propionate [Cmax (pg/mL) measurement] in human plasma using high performance liquid chromatography (HPLC) with mass spectrometric detection. Approximately 5 mL of blood is collected from each subject at 10 different timepoints over an 8-hour period, for a total of 50 mL. The timepoints are: Pre-dose; 5 minutes, 10 minutes, 15 minutes, 30 minutes, 1 hour, 1.5 hours, 3 hours, 6 hours and 8 hours post-dose.

8 hours, 1 to 2 weeks before randomization
Assessment of pharmacokinetics - tmax (h)
Časové okno: 8 hours, 1 to 2 weeks before randomization

PK Laboratory to determine the concentrations of fluticasone propionate [tmax (h) measurement] in human plasma using high performance liquid chromatography (HPLC) with mass spectrometric detection. Approximately 5 mL of blood is collected from each subject at 10 different timepoints over an 8-hour period, for a total of 50 mL. The timepoints are: Pre-dose; 5 minutes, 10 minutes, 15 minutes, 30 minutes, 1 hour, 1.5 hours, 3 hours, 6 hours and 8 hours post-dose.

8 hours, 1 to 2 weeks before randomization
Assessment of pharmacokinetics - t1/2 (h)
Časové okno: 8 hours, 1 to 2 weeks before randomization

PK Laboratory to determine the concentrations of fluticasone propionate [t1/2 (h) measurement] in human plasma using high performance liquid chromatography (HPLC) with mass spectrometric detection. Approximately 5 mL of blood is collected from each subject at 10 different timepoints over an 8-hour period, for a total of 50 mL. The timepoints are: Pre-dose; 5 minutes, 10 minutes, 15 minutes, 30 minutes, 1 hour, 1.5 hours, 3 hours, 6 hours and 8 hours post-dose.

8 hours, 1 to 2 weeks before randomization

Spolupracovníci a vyšetřovatelé

Zde najdete lidi a organizace zapojené do této studie.

Spolupracovníci

Vyšetřovatelé

  • Studijní židle: Amy Manley, Paratek Pharma

Termíny studijních záznamů

Tato data sledují průběh záznamů studie a předkládání souhrnných výsledků na ClinicalTrials.gov. Záznamy ze studií a hlášené výsledky jsou před zveřejněním na veřejné webové stránce přezkoumány Národní lékařskou knihovnou (NLM), aby se ujistily, že splňují specifické standardy kontroly kvality.

Hlavní termíny studia

Začátek studia (Aktuální)

31. prosince 2018

Primární dokončení (Aktuální)

31. března 2026

Dokončení studie (Aktuální)

11. června 2026

Termíny zápisu do studia

První předloženo

23. října 2018

První předloženo, které splnilo kritéria kontroly kvality

16. listopadu 2018

První zveřejněno (Aktuální)

20. listopadu 2018

Aktualizace studijních záznamů

Poslední zveřejněná aktualizace (Aktuální)

18. září 2026

Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality

15. září 2026

Naposledy ověřeno

1. září 2026

Více informací

Termíny související s touto studií

Další identifikační čísla studie

  • OPN-FLU-NP-3103

Informace o lécích a zařízeních, studijní dokumenty

Studuje lékový produkt regulovaný americkým FDA

Ano

Studuje produkt zařízení regulovaný americkým úřadem FDA

Ne

Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .

Předplatit